Literature DB >> 33404067

Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus.

Melissa E Badowski1, Nicholas Britt2, Emily C Huesgen3, Michelle M Lewis4, Misty M Miller5, Kathleen Nowak6, Elizabeth Sherman7, Renata O Smith1.   

Abstract

Pharmacotherapy considerations are often a concern for transgender individuals who are living with human immunodeficiency virus (HIV) due to concerns for drug-drug interactions between their hormone and antiretroviral therapies. Many of the first-line therapies offered to patients for the management of HIV have reduced concerns for safety, resistance, and drug-drug interactions. In this review, we highlight common medications and important considerations for caring for transgender people living with HIV.
© 2021 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  antiretroviral therapy; hormone therapy; human immunodeficiency virus; transgender

Mesh：

Year:  2021        PMID： 33404067      PMCID： PMC8128446          DOI： 10.1002/phar.2499

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  55 in total

1.  Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

Authors:  R Dittrich; H Binder; S Cupisti; I Hoffmann; M W Beckmann; A Mueller
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-12       Impact factor: 2.949

Review 2.  Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses.

Authors:  Mohamed B Elamin; Magaly Zumaeta Garcia; Mohammad Hassan Murad; Patricia J Erwin; Victor M Montori
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-16       Impact factor: 3.478

Review 3.  Barriers to healthcare for transgender individuals.

Authors:  Joshua D Safer; Eli Coleman; Jamie Feldman; Robert Garofalo; Wylie Hembree; Asa Radix; Jae Sevelius
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

4.  Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.

Authors:  Jason Yen-Ping Ho; Ming-Jer Chen; Wayne Huey-Herng Sheu; Yu-Chiao Yi; Andy Chi-Wei Tsai; Hwa-Fen Guu; Esther Shih-Chu Ho
Journal:  Hum Reprod       Date:  2006-06-28       Impact factor: 6.918

Review 5.  Migraine and estrogen.

Authors:  Nu Cindy Chai; B Lee Peterlin; Anne H Calhoun
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

Review 6.  Clinical review: Breast development in trans women receiving cross-sex hormones.

Authors:  Katrien Wierckx; Louis Gooren; Guy T'Sjoen
Journal:  J Sex Med       Date:  2014-03-12       Impact factor: 3.802

7.  Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism.

Authors:  J C Prior; Y M Vigna; D Watson
Journal:  Arch Sex Behav       Date:  1989-02

Review 8.  Oestrogen and anti-androgen therapy for transgender women.

Authors:  Vin Tangpricha; Martin den Heijer
Journal:  Lancet Diabetes Endocrinol       Date:  2016-12-02       Impact factor: 32.069

9.  Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics.

Authors:  Andrea Thurman; Thomas Kimble; Peter Hall; Jill L Schwartz; David F Archer
Journal:  Contraception       Date:  2012-12-22       Impact factor: 3.375

10.  Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals.

Authors:  H Asscheman; L J Gooren; J Assies; J P Smits; R de Slegte
Journal:  Clin Endocrinol (Oxf)       Date:  1988-06       Impact factor: 3.478
View more
  1 in total

1.  Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population.

Authors:  Mark Lieber; Matthew M Hamill; Paul Pham; Elyse Pine; Jill Crank; Maunank Shah
Journal:  Open Forum Infect Dis       Date:  2022-03-23       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.